Description
Recombinant Human Antibody (2F2) is capable of binding to CD20, expressed in HEK 293 cells. Expressed as the combination of a heavy chain (HC) containing VH from anti-CD20 mAb and CH1-3 region of human IgG1 and a light chain (LC) encoding VL from anti-CD20 proteins mAb and CL of human kappa light chain. Exists as a disulfide linked dimer of the HC and LC hetero-dimer under non-reducing condition. This antibody is a fully human anti-CD20 antibody that is currently in phase III clinical trial for several types of malignancies and autoimmune diseases and is one of the most promising antiCD20 drugs.
Target
MS4A1
Target Alias Names
MS4A1, membrane-spanning 4-domains, subfamily A, member 1, B1, S7, Bp35, CD20, CVID5, LEU-16, B-lymphocyte antigen CD20, CD20 antigen, CD20 receptor, leukocyte surface antigen Leu-16, B-lymphocyte cell-surface antigen B1
Isotypes/Mimetics
Human IgG1, κ
Animal-Derived Biomaterials Used
None
Sequence Available
No
Original Discovery Method
Human-derived phage display
Original Discovery Information Provided On Datasheet
No
Antibody/Binder Origins
Animal-free discovery, In vitro recombinant expression